Table 2.

Patient-level statistical analysis of serum PTH levels (pg/mL) over time.

	Mean Difference of Initial PTH and Average PTH 31–180 Days in CP	Mean Difference of Initial Dose and Average Dose 181–365 Days in CP	Mean Difference of Initial Dose and Average Dose >365 Days in CP
MS patients	−16.1 pg/mL PTH (p < 0.001)	−19.3 pg/mL PTH (p < 0.001)	−25.3 pg/mL PTH (p < 0.001)
Non-MS patients	−18.4 pg/mL PTH (p < 0.001)	−22.0 pg/mL PTH (p < 0.001)	−28.3 pg/mL PTH (p < 0.001)

While Figure 5 displays the PTH measurements in all laboratory investigations within a given time frame after protocol initiation, Table 2 presents the statistical results on a per-patient basis to account for the repeated measurement structure. For every MS and non-MS patient, all PTH measurements within a given time frame (e.g., 31–180 days in CP) are averaged. We then report the mean difference of these average PTH levels to the initial level across patients as well as the p-values resulting from a Wilcoxon signed-rank test.